elbasvir + grazoprevir + sofosbuvir + ribavirin

This drug is a **four-drug combination therapy** for chronic hepatitis C virus (HCV) infection, specifically combining **elbasvir**, **grazoprevir**, **sofosbuvir**, and **ribavirin**. Elbasvir is an NS5A inhibitor that interferes with HCV RNA replication and virion assembly. Grazoprevir is a NS3/4A protease inhibitor, blocking polyprotein cleavage necessary for viral replication. Sofosbuvir is a nucleotide NS5B polymerase inhibitor, also interfering with viral replication. Ribavirin is a nucleoside analogue, whose mechanism in HCV is not fully understood but likely involves inhibition of viral RNA synthesis and mutagenesis. This combination is highly potent as it targets **multiple distinct stages of the HCV life cycle**. The regimen is considered in clinical contexts (such as resistant/complex cases), but is not standard, and individual combinations (often two or three drugs such as elbasvir + grazoprevir with ribavirin, or sofosbuvir + ribavirin) are more commonly used and approved for specific HCV genotypes[1][2][3][4][6].

Brand names

ZepatierSovaldi

Other names

elbasvir/grazoprevir + sofosbuvir + ribavirinC-RESCUE regimen